Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Encell Co., Ltd. (456070:KRX), powered by AI.
Encell Co., Ltd. is currently trading at ₩14,360. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Encell Co., Ltd. on Alpha Lenz.
Encell Co., Ltd.'s P/E ratio is -9.8.
“Encell Co., Ltd. trades at a P/E of -9.8 (undervalued) with modest ROE of -36.8%.”
Ask for details →Encell Co., Ltd. is a company specializing in the biotechnology and pharmaceuticals sectors. Its primary function is to develop and produce innovative therapies and health solutions aimed at addressing various medical needs. With a strong emphasis on research and development, Encell Co., Ltd. engages in creating novel drugs and treatment methodologies that have the potential to significantly impact the healthcare industry. The company collaborates extensively with research institutions and medical professionals to streamline its development processes and enhance efficacy in its offerings. As a participant in the fast-evolving biotech and pharmaceutical industries, Encell Co., Ltd. plays a vital role in the global efforts to improve health outcomes and advance medical technologies. Headquartered in South Korea, it is part of a significant financial market segment that sees continuous influxes of investment directed towards innovative health solutions, reflecting its importance in contributing to public health and scientific advancement.
“Encell Co., Ltd. trades at a P/E of -9.8 (undervalued) with modest ROE of -36.8%.”
Ask for details →Encell Co., Ltd. (ticker: 456070) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $158.4B.
The current price is ₩14,360 with a P/E ratio of -9.83x and P/B of 4.02x.
ROE is -36.79% and operating margin is -339.26%. Annual revenue is $5.3B.